Strict control of auxiliary drugs, the richest doctor is going bankrupt!

The author, "Dr. Richest Doctor" Holding Company filed for bankruptcy recently, by the former Heilongjiang richest man, ophthalmologist Zhu Jiman mainly controlled by the listed pharmaceutical company Reputation Heng Pharmaceuticals issued a notice that its majority shareholder Yu Heng Group has entered bankruptcy restructuring proceedings.
's announcement showed that as a result of the bankruptcy restructuring of the holding company, Yu Heng Group's holding of more than 700 million shares of Yu heng Pharmaceuticals was frozen, based on the July 7 closing price, the value of frozen assets of 2.533 billion yuan.
It is understood that Yu heng Pharmaceuticals was founded in 2000, is Zhu Jiman Holdings' first joint-stock company, listed in 2010, is a pharmaceutical industry as the main line, pharmaceutical business as the core, covering scientific research, production, marketing and other fields of high-tech enterprise groups.
According to the 21st Century Economic Journal, from the perspective of the equity structure, as of July 9, 2020, industrial and commercial information shows that the controlling shareholder of Yuheng Pharmaceuticals is Yuheng Group, holding 822 million shares, accounting for 37.39 percent of the company's total share capital, after penetration of the company's actual controlling person Zhu Jiman, a total of 26.04 percent of the shares.
, Zhu Jiman graduated from Xi'an Medical University (now Xi'an Jiaojiao University School of Medicine) and worked as an ophthalmologist at Xi'an Electric Power Center Hospital.
2000, Zhu Jiman bought a subsidiary of Heilongjiang Rehabilitation Research Institute, which was on the verge of bankruptcy, for $1.68 million and converted it into Yu heng Pharmaceuticals, which went public in 2010.
2015, 50-year-old Zhu Jiman was ranked 317th on Forbes' list of the richest Chinese with $1.2 billion in assets.
2018, Zhu Jiman and his wife, who are worth 10.5 billion pounds, will be the richest man in Heilongjiang.
The main products into the auxiliary drug monitoring directory, operating conditions are not optimistic although Yu Heng Pharmaceuticals repeatedly said in the announcement, and Yu Heng Group in assets, business, finance and other aspects of independence, Yu Heng Group into bankruptcy restructuring proceedings will not affect the company's normal operations.
but in fact, Yu Heng Pharmaceuticals has previously said that by the "two-vote system", auxiliary drug key monitoring directory, medical insurance fee control and other policies, Yu Heng Pharmaceutical's operating conditions are not optimistic.
the company's previously acquired core business is the wholly-owned subsidiary of Auxiliary Medicines Shanghai Huato, Nanjing Wanchuan, Pude Pharmaceuticals, the main product sales and prices continue to decline, operating performance fell sharply.
's 2019 annual report showed its first loss since it went public in 2019, with net profit for the reporting period at -2,662 million yuan, down 2214.30% year-on-year.
to reduce debt and promote transformation, Yu heng Pharmaceuticals to sell core assets, equity and other ways in exchange for cash flow.
2019, Yu heng Pharmaceuticals sold a 100% stake in its premium asset, Ono Pharmaceuticals, to China Resources for RMB1.420 billion.
it is understood that in 2018, Ono Pharmaceuticals' profit contribution ranks first among its subsidiaries.
the first quarter of 2020, Yu Heng Pharmaceutical's net profit turned a loss of 659 million yuan due to the transfer of Aono Pharmaceuticals' equity stake and the receipt of government subsidies to achieve a non-recurring profit and loss of 701 million yuan.
loss of $42.8695 million after deducting non-recurring gains and losses.
Double catalog adjustment, pharmaceutical companies will usher in a big shuffle "two-vote system" refers to the drug from the pharmaceutical factory to the first-level dealers to open an invoice, dealers sell to the hospital to open another invoice, with two votes to replace the previous multi-ticket, reduce the circulation of the layer of price increases, reduce the cost of drug circulation.
"two-vote system" has blocked the traditional way of bribery of hospitals by pharmaceutical companies and compressed the market for pharmaceutical companies.
and complementary drugs are considered "one-stop medicines", as opposed to therapeutic drugs, refers to the role of a disease is clearly complementary drugs - such drugs alone, can not achieve the purpose of treating the disease.
years, complementary drug use has become a major disaster area for overuse and benefit transmission.
2018, the General Office of the National Health And Health Commission issued the Notice on doing a good job in the clinical application management of complementary drugs (National Health Administration Medical Letter (2018) No. 1112), requiring all secondary and above medical institutions to establish a national list of complementary drugs as soon as possible, according to which to formulate a national list of complementary drugs, and adjust at least once a year.
aim is to strengthen the clinical application management of auxiliary drugs in medical institutions, standardize the clinical application behavior of auxiliary drugs, and improve the level of rational drug use.
State Health And Health Commission Medical Administration Deputy Director Jia Yahui previously in an interview with CCTV "Focus Interview", said that the goal of this reform is to rational use of drugs, unreasonable drug use of the ingredients squeezed out, to ensure that the National Health Insurance Fund is really used on the cutting edge.
June 11, 2019, the first batch of state-focused monitoring of rational drug catalog of 20 drugs announced, including Yuheng Pharmaceutical's wholly-owned subsidiary Shanghai Huato, Nanjing Wanchuan's main product injection sodium phosphate creatine;
The first batch of national key monitoring reasonable drug catalog is not only Yu Heng pharmaceutical industry, the national auxiliary drug monitoring catalog, medical insurance catalog on other pharmaceutical companies also have a great impact, Shutai Shen (Beijing) Biopharmaceutical Co., Ltd.'s main product "rat nerve growth factor" is a good example.
In July 2019, rat nerve growth factors were included in the National Health Council's first batch of national key monitoring rational drug catalog, and then in 2019 the medical insurance catalog adjustment process was transferred out of the health insurance catalog, affected by the two catalogs, the amount of sales of this product showed a cliff-edge decline.
2019 Annual Report shows that Shutai's neurogrowth factor sales revenue of 340 million, accounting for 51.81 percent of the company's revenue, revenue decreased 37.22 percent year-on-year, which is still included in the monitoring directory less than half a year.
industry analysis, in the implementation of the national health insurance catalog, auxiliary drug monitoring directory, two-vote system policy, to auxiliary drug as the core business or re-sell, light research and development of some traditional pharmaceutical companies may usher in a big shuffle.
.